JUL. 25. 2005 1:45PM AVENTIS US PAT DEPT

RECEIVED CENTRAL FAX CENTER

NO. 7048 P. 1

JUL 2 5 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pacerwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. Application Number 10/796.466 TRANSMITTAL Filing Date March 09, 2004 FORM First Named Inventor Joachim BRENDEL et al. Art Unit 1625 **Examiner Name** MORRIS, Patricia L. (to be used for all correspondence after initial filing) Attorney Docket Number **DEAV2003/0024 US NP** Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences 7 Appeal Communication to TC Petitlon Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Endosure(s) (please Identify Terminal Disclalmen Extension of Time Request below): Request for Refund Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name seph D. Rossi Date Reg. No. July 25, 2005 47.038 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 11 Signature Date Typed or printed name Paul Irvine July 25, 2005

This collection of information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Information Critical Commence of the process of the Chief Information Officer, U.S. Patent and Trademark Offices, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

NO. 7048_T P. 2

JUL 2 5 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Morris, Patricia

BRENDEL, et al.

Art Unit:

1625

Application No.: 10/796,466

Filed: March 9, 2004

CERTIFICATE OF TRANSMISSION I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450, at 571-273-8300, on

Title:

2-(BUTYL-1-SULFONYLAMINO)-N-[1(R)-(6-METHOXYPYRIDIN-3-

YL)PROPYL] BENZAMIDE, ITS USE

AS A MEDICAMENT, AND

PHARMACEUTICAL

PREPARATIONS COMPRISING IT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REPLY PUSUANT TO 37 C.F.R. § 1.111

In response to the Office Action dated April 25, 2005 ("the Action"), reconsideration

is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.
- Remarks/Arguments begin on page 4 of this paper.